Texas Children Hospital v. Aviv Barr and Ela Barr, Individally and as Next Friends of MB, a Minor Child

CourtCourt of Appeals of Texas
DecidedNovember 19, 2020
Docket01-20-00146-CV
StatusPublished

This text of Texas Children Hospital v. Aviv Barr and Ela Barr, Individally and as Next Friends of MB, a Minor Child (Texas Children Hospital v. Aviv Barr and Ela Barr, Individally and as Next Friends of MB, a Minor Child) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Texas Children Hospital v. Aviv Barr and Ela Barr, Individally and as Next Friends of MB, a Minor Child, (Tex. Ct. App. 2020).

Opinion

Opinion issued November 19, 2020

In The

Court of Appeals For The

First District of Texas ———————————— NO. 01-20-00146-CV ——————————— TEXAS CHILDREN’S HOSPITAL, Appellant V. AVIV BARR AND ELA BARR, INDIVIDALLY AND AS NEXT FRIENDS OF M.B., A MINOR CHILD, Appellees

On Appeal from the 189th District Court Harris County, Texas Trial Court Case No. 2019-12365

MEMORANDUM OPINION

Appellees, Aviv Barr and Ela Barr, individually and as next friends of M.B.,

a minor child, sued Texas Children’s Hospital (TCH) and others for negligence in connection with a brain surgery performed on M.B.1 After several objections and

subsequent amendments to the Barrs’ expert report, TCH moved to dismiss the

Barrs’ claims, arguing that their amended expert report was insufficient as to

causation. The trial court denied the motion to dismiss. In its sole issue, TCH argues

that the trial court abused its discretion in denying TCH’s objections to the amended

expert report and motion to dismiss. Because we conclude that the expert affidavit

was sufficient, we affirm.

Background

The Barrs’ minor daughter, M.B., underwent a minimally-invasive brain

surgery to treat her epilepsy at TCH in Houston.2 On July 20, 2018, Dr. Daniel Curry

performed the surgery at TCH using the NeuroBlate system, which is an MRI-

guided3 laser ablation device that had been subject to a recall by the Food and Drug

Administration (FDA), prior to M.B.’s surgery, in October 2017. M.B. was

discharged from TCH on July 22, 2018, but she later experienced symptoms such as

1 The Barrs also sued Dr. Daniel Curry, the surgeon, and Monteris, the manufacturer of the ablation laser that allegedly malfunctioned, but they are not parties to this appeal. 2 We accept the facts included in Dr. Avellino’s report for the limited purpose of this appeal. See Marino v. Wilkins, 393 S.W.3d 318, 320 n.1 (Tex. App.—Houston [1st Dist.] 2012, pet. denied); see also Bowie Mem’l Hosp. v. Wright, 79 S.W.3d 48, 53 (Tex. 2002) (review of Chapter 74 report is limited to four corners of report). 3 The NeuroBlate system used Magnetic Resonance Imaging to guide the surgeon’s use of the laser probe. 2 dizziness, vomiting, and loss of consciousness and was admitted to St. Mary’s

Medical Center in Florida for further treatment. Doctors at St. Mary’s concluded that

M.B. had a ruptured pseudoaneurysm and treated her with additional surgery, and

M.B. was then moved to a hospital in Tel Aviv, Israel for further rehabilitation. The

Barrs allege that M.B. has suffered permanent brain damage.

The Barrs filed suit against TCH, Dr. Curry, and Monteris, the manufacturer

of the NeuroBlate system. The Barrs alleged product-liability claims against

Monteris, and they alleged that Dr. Curry was negligent in several ways, including

that he failed to disclose to the Barrs that the NeuroBlate system had been recalled

by the FDA when he obtained their consent for the surgery and that he failed to order

vascular studies after M.B. first experienced a brain bleed during her surgery in July

2018 that would have identified the pseudoaneurysm before its rupture. Finally, the

Barrs alleged that TCH was negligent in permitting Dr. Curry to use its recalled

NeuroBlate laser probe to perform M.B.’s surgery. The Barrs supported their

pleadings with the expert report of Dr. Anthony Avellino, a pediatric and adult

neurosurgeon.4

Dr. Avellino’s report, as amended to address deficiencies pointed out by TCH,

provided details regarding the FDA’s recall of the NeuroBlate laser probe. Dr.

4 The Barrs also provided an additional expert report from an engineer regarding the malfunctioning of the laser probe, but that report is not relevant to this appeal. 3 Avellino stated in his report that this recall was due to “unexpected heating and probe

damage, which ‘could cause unanticipated heating of surrounding brain tissue, or

damage the tip of the probe, and allow the CO2 cooling gas inside the probe to leak

into the brain.’” He stated that, on October 5, 2017, the device was the subject of a

Class I recall by the FDA, which recommended that health care providers “should

strongly consider treating patients using alternative procedures if available.” He also

indicated that a Class I recall meant “by definition [the malfunctioning device] can

cause death or serious injury.” Monteris likewise sent notices to healthcare providers

between October and December 2017 about the unintentional heating and advised

doctors to “take certain precautionary steps to mitigate the risk to patients, including

limiting MRI scans while the probe is in the patient.” However, on March 22, 2018,

the FDA subsequently provided a “Safety Alert,” informing health care providers

that the steps recommended by Monteris were “not sufficient to mitigate the risk of

unintended laser probe heating.”

On April 24, 2018, the FDA warned health care providers “that the MR

thermometry, which is used to monitor the changes in temperature at the laser

ablation site, was potentially inaccurate and may not account for continued spread

of energy to the surrounding brain tissue.” Dr. Avellino further stated that the FDA

stated in its notice that several adverse events were associated with use of the

NeuroBlate system: “neurological deficits, increased intracerebral edema or

4 pressure, intracranial bleeding, and/or visual changes.” Monteris continued to work

on designing a new laser probe for the NeuroBlate system that replaced the metal

thermocouple with a new, non-metallic fiber optic sensor, “thus eliminating any risk

of unintended probe heating.” This design was submitted to the FDA on July 30,

2018, ten days after M.B.’s surgery. On November 8, 2018, the FDA notified

healthcare providers that Monteris had received FDA clearance for the new probe

and stated that the safety risks associated with the old probe remained.

Regarding M.B.’s surgery specifically, Dr. Avellino reviewed M.B.’s medical

records from TCH and noted that “[p]ostoperative head CT imaging on 7/21/2018

revealed a small amount of acute hemorrhage at the lesion site, intraventricular

hemorrhage, and subarachnoid hemorrhage in the ambient cistern with an abnormal

irregular rounded shaped focal lesion lateral to the ambient cistern suspicious for an

aneurysm.” He noted that, despite this head CT, “the cranial vasculature was not

evaluated with a head CT angiogram to rule out an aneurysm and no explanation

was given for the hemorrhages outside the lesion bed.” Rather, Dr. Curry relied on

imaging that showed the bleeding appeared to be resolving, and M.B. was

discharged. She later sought further treatment at St. Mary’s Medical Center after she

“became comatose.”

When M.B. was admitted to St. Mary’s on August 7, 2018, “head CT imaging

showed a large acute right temporal intracerebral hematoma with diffuse

5 intraventricular hemorrhage, acute hydrocephalus, and uncal herniation.” She

underwent emergency surgery to reduce the swelling in her brain, and further

imaging revealed that she had a pseudoaneurysm, which was treated at St. Mary’s.

M.B. was then released for “further rehabilitation” to a hospital in Tel Aviv “with

permanent neurologic sequelae.”

Regarding the standard of care and breach with regard to TCH, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Larson v. Downing
197 S.W.3d 303 (Texas Supreme Court, 2006)
Costello v. Christus Santa Rosa Health Care Corp.
141 S.W.3d 245 (Court of Appeals of Texas, 2004)
American Transitional Care Centers of Texas, Inc. v. Palacios
46 S.W.3d 873 (Texas Supreme Court, 2001)
Bowie Memorial Hospital v. Wright
79 S.W.3d 48 (Texas Supreme Court, 2002)
Angela Cornejo and Carlos Portillo v. Stephen J. Hilgers, M.D.
446 S.W.3d 113 (Court of Appeals of Texas, 2014)
Barbara Marino, M.D. v. Wendy Wilkins
393 S.W.3d 318 (Court of Appeals of Texas, 2012)
Jelinek v. Casas
328 S.W.3d 526 (Texas Supreme Court, 2010)
In re Michael V. Kelly, Ii, M.D., Compounding Plus LLC
543 S.W.3d 383 (Court of Appeals of Texas, 2018)
Baty v. Olga Futrell, Crna, & Complete Anesthesia Care, P.C.
543 S.W.3d 689 (Texas Supreme Court, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Texas Children Hospital v. Aviv Barr and Ela Barr, Individally and as Next Friends of MB, a Minor Child, Counsel Stack Legal Research, https://law.counselstack.com/opinion/texas-children-hospital-v-aviv-barr-and-ela-barr-individally-and-as-next-texapp-2020.